Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.

Saved in:
Bibliographic Details
Title: Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.
Authors: Di Federico A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Hong L; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston., Elkrief A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York., Thummalapalli R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York., Cooper AJ; Massachusetts General Hospital, Boston, USA., Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Digumarthy S; Massachusetts General Hospital, Boston, USA., Alessi JV; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Gogia P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York., Pecci F; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Makarem M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Gandhi MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Garbo E; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Saini A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., De Giglio A; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna., Favorito V; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna., Scalera S; Clinical Trial Center, Biostatistics and Bioinformatics Division, IRCCS Regina Elena National Cancer Institute, Rome., Cipriani L; Clinical Trial Center, Biostatistics and Bioinformatics Division, IRCCS Regina Elena National Cancer Institute, Rome., Marinelli D; Department of Experimental Medicine, Sapienza University, Rome, Italy., Haradon D; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Nguyen T; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Haradon J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Voligny E; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Vaz V; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston., Gelsomino F; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna., Sperandi F; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna., Melotti B; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna., Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York., Zhang J; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston., Gibbons DL; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston., Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston., Nishino M; Department of Radiology, Brigham and Women's Hospital, Boston; Department of Imaging, Dana-Farber Cancer Institute, Boston., Lindsay J; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston., Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston., Pfaff K; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston., Sholl LM; Department of Pathology, Brigham and Women's Hospital, Boston., Wang X; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston., Johnson BE; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA., Rekhtman N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York., Maugeri-Saccà M; Clinical Trial Center, Biostatistics and Bioinformatics Division, IRCCS Regina Elena National Cancer Institute, Rome., Heist RS; Massachusetts General Hospital, Boston, USA., Ardizzoni A; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna., Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA., Arbour KC; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York., Schoenfeld AJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York., Vokes NI; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston., Luo J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA. Electronic address: Jia_Luo@dfci.harvard.edu.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2025 Mar; Vol. 36 (3), pp. 297-308. Date of Electronic Publication: 2024 Dec 03.
Publication Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1569-8041
DOI:10.1016/j.annonc.2024.11.014